Cargando…

Why onchocerciasis transmission persists after 15 annual ivermectin mass drug administrations in South-West Cameroon

INTRODUCTION: Onchocerciasis is targeted for elimination mainly with annual community-directed treatment with ivermectin (CDTI). High infection levels have been reported in South-West Cameroon, despite ≥15 years of CDTI. The aim of this study was to assess factors associated with continued onchocerc...

Descripción completa

Detalles Bibliográficos
Autores principales: Forrer, Armelle, Wanji, Samuel, Obie, Elisabeth Dibando, Nji, Theobald Mue, Hamill, Louise, Ozano, Kim, Piotrowski, Helen, Dean, Laura, Njouendou, Abdel J, Ekanya, Relindis, Ndongmo, Winston Patrick Chounna, Fung, Ebua Gallus, Nnamdi, Dum-Buo, Abong, Raphael A, Beng, Amuam Andrew, Eyong, Mathias Esum, Ndzeshang, Bertrand L, Nkimbeng, Desmond Akumtoh, Teghen, Samuel, Suireng, Anicetus, Ashu, Ernerstine Ebot, Kah, Emmanuel, Murdoch, Michele M, Thomson, Rachael, Theobald, Sally, Enyong, Peter, Turner, Joseph D, Taylor, Mark J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802695/
https://www.ncbi.nlm.nih.gov/pubmed/33431378
http://dx.doi.org/10.1136/bmjgh-2020-003248
_version_ 1783635803285487616
author Forrer, Armelle
Wanji, Samuel
Obie, Elisabeth Dibando
Nji, Theobald Mue
Hamill, Louise
Ozano, Kim
Piotrowski, Helen
Dean, Laura
Njouendou, Abdel J
Ekanya, Relindis
Ndongmo, Winston Patrick Chounna
Fung, Ebua Gallus
Nnamdi, Dum-Buo
Abong, Raphael A
Beng, Amuam Andrew
Eyong, Mathias Esum
Ndzeshang, Bertrand L
Nkimbeng, Desmond Akumtoh
Teghen, Samuel
Suireng, Anicetus
Ashu, Ernerstine Ebot
Kah, Emmanuel
Murdoch, Michele M
Thomson, Rachael
Theobald, Sally
Enyong, Peter
Turner, Joseph D
Taylor, Mark J
author_facet Forrer, Armelle
Wanji, Samuel
Obie, Elisabeth Dibando
Nji, Theobald Mue
Hamill, Louise
Ozano, Kim
Piotrowski, Helen
Dean, Laura
Njouendou, Abdel J
Ekanya, Relindis
Ndongmo, Winston Patrick Chounna
Fung, Ebua Gallus
Nnamdi, Dum-Buo
Abong, Raphael A
Beng, Amuam Andrew
Eyong, Mathias Esum
Ndzeshang, Bertrand L
Nkimbeng, Desmond Akumtoh
Teghen, Samuel
Suireng, Anicetus
Ashu, Ernerstine Ebot
Kah, Emmanuel
Murdoch, Michele M
Thomson, Rachael
Theobald, Sally
Enyong, Peter
Turner, Joseph D
Taylor, Mark J
author_sort Forrer, Armelle
collection PubMed
description INTRODUCTION: Onchocerciasis is targeted for elimination mainly with annual community-directed treatment with ivermectin (CDTI). High infection levels have been reported in South-West Cameroon, despite ≥15 years of CDTI. The aim of this study was to assess factors associated with continued onchocerciasis transmission and skin disease. METHODS: A large-scale cross-sectional study was conducted in 2017 in 20 communities in a loiasis-risk area in South-West Cameroon. A mixed-methods approach was used. Associations between infection levels, skin disease and adherence to CDTI were assessed using mixed regression modelling. Different community members’ perception and acceptability of the CDTI strategy was explored using semi-structured interviews. RESULTS: Onchocerciasis prevalence was 44.4% among 9456 participants. 17.5% of adults were systematic non-adherers and 5.9% participated in ≥75% of CDTI rounds. Skin disease affected 1/10 participants, including children. Increasing self-reported adherence to CDTI was associated with lower infection levels in participants aged ≥15 years but not in children. Adherence to CDTI was positively influenced by perceived health benefits, and negatively influenced by fear of adverse events linked with economic loss. Concern of lethal adverse events was a common reason for systematic non-adherence. CONCLUSION: CDTI alone is unlikely to achieve elimination in those high transmission areas where low participation is commonly associated with the fear of adverse events, despite the current quasi absence of high-risk levels of loiasis. Such persisting historical memories and fear of ivermectin might impact adherence to CDTI also in areas with historical presence but current absence of loiasis. Because such issues are unlikely to be tackled by CDTI adaptive measures, alternative strategies are needed for onchocerciasis elimination where negative perception of ivermectin is an entrenched barrier to community participation in programmes.
format Online
Article
Text
id pubmed-7802695
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-78026952021-01-21 Why onchocerciasis transmission persists after 15 annual ivermectin mass drug administrations in South-West Cameroon Forrer, Armelle Wanji, Samuel Obie, Elisabeth Dibando Nji, Theobald Mue Hamill, Louise Ozano, Kim Piotrowski, Helen Dean, Laura Njouendou, Abdel J Ekanya, Relindis Ndongmo, Winston Patrick Chounna Fung, Ebua Gallus Nnamdi, Dum-Buo Abong, Raphael A Beng, Amuam Andrew Eyong, Mathias Esum Ndzeshang, Bertrand L Nkimbeng, Desmond Akumtoh Teghen, Samuel Suireng, Anicetus Ashu, Ernerstine Ebot Kah, Emmanuel Murdoch, Michele M Thomson, Rachael Theobald, Sally Enyong, Peter Turner, Joseph D Taylor, Mark J BMJ Glob Health Original Research INTRODUCTION: Onchocerciasis is targeted for elimination mainly with annual community-directed treatment with ivermectin (CDTI). High infection levels have been reported in South-West Cameroon, despite ≥15 years of CDTI. The aim of this study was to assess factors associated with continued onchocerciasis transmission and skin disease. METHODS: A large-scale cross-sectional study was conducted in 2017 in 20 communities in a loiasis-risk area in South-West Cameroon. A mixed-methods approach was used. Associations between infection levels, skin disease and adherence to CDTI were assessed using mixed regression modelling. Different community members’ perception and acceptability of the CDTI strategy was explored using semi-structured interviews. RESULTS: Onchocerciasis prevalence was 44.4% among 9456 participants. 17.5% of adults were systematic non-adherers and 5.9% participated in ≥75% of CDTI rounds. Skin disease affected 1/10 participants, including children. Increasing self-reported adherence to CDTI was associated with lower infection levels in participants aged ≥15 years but not in children. Adherence to CDTI was positively influenced by perceived health benefits, and negatively influenced by fear of adverse events linked with economic loss. Concern of lethal adverse events was a common reason for systematic non-adherence. CONCLUSION: CDTI alone is unlikely to achieve elimination in those high transmission areas where low participation is commonly associated with the fear of adverse events, despite the current quasi absence of high-risk levels of loiasis. Such persisting historical memories and fear of ivermectin might impact adherence to CDTI also in areas with historical presence but current absence of loiasis. Because such issues are unlikely to be tackled by CDTI adaptive measures, alternative strategies are needed for onchocerciasis elimination where negative perception of ivermectin is an entrenched barrier to community participation in programmes. BMJ Publishing Group 2021-01-11 /pmc/articles/PMC7802695/ /pubmed/33431378 http://dx.doi.org/10.1136/bmjgh-2020-003248 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Original Research
Forrer, Armelle
Wanji, Samuel
Obie, Elisabeth Dibando
Nji, Theobald Mue
Hamill, Louise
Ozano, Kim
Piotrowski, Helen
Dean, Laura
Njouendou, Abdel J
Ekanya, Relindis
Ndongmo, Winston Patrick Chounna
Fung, Ebua Gallus
Nnamdi, Dum-Buo
Abong, Raphael A
Beng, Amuam Andrew
Eyong, Mathias Esum
Ndzeshang, Bertrand L
Nkimbeng, Desmond Akumtoh
Teghen, Samuel
Suireng, Anicetus
Ashu, Ernerstine Ebot
Kah, Emmanuel
Murdoch, Michele M
Thomson, Rachael
Theobald, Sally
Enyong, Peter
Turner, Joseph D
Taylor, Mark J
Why onchocerciasis transmission persists after 15 annual ivermectin mass drug administrations in South-West Cameroon
title Why onchocerciasis transmission persists after 15 annual ivermectin mass drug administrations in South-West Cameroon
title_full Why onchocerciasis transmission persists after 15 annual ivermectin mass drug administrations in South-West Cameroon
title_fullStr Why onchocerciasis transmission persists after 15 annual ivermectin mass drug administrations in South-West Cameroon
title_full_unstemmed Why onchocerciasis transmission persists after 15 annual ivermectin mass drug administrations in South-West Cameroon
title_short Why onchocerciasis transmission persists after 15 annual ivermectin mass drug administrations in South-West Cameroon
title_sort why onchocerciasis transmission persists after 15 annual ivermectin mass drug administrations in south-west cameroon
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802695/
https://www.ncbi.nlm.nih.gov/pubmed/33431378
http://dx.doi.org/10.1136/bmjgh-2020-003248
work_keys_str_mv AT forrerarmelle whyonchocerciasistransmissionpersistsafter15annualivermectinmassdrugadministrationsinsouthwestcameroon
AT wanjisamuel whyonchocerciasistransmissionpersistsafter15annualivermectinmassdrugadministrationsinsouthwestcameroon
AT obieelisabethdibando whyonchocerciasistransmissionpersistsafter15annualivermectinmassdrugadministrationsinsouthwestcameroon
AT njitheobaldmue whyonchocerciasistransmissionpersistsafter15annualivermectinmassdrugadministrationsinsouthwestcameroon
AT hamilllouise whyonchocerciasistransmissionpersistsafter15annualivermectinmassdrugadministrationsinsouthwestcameroon
AT ozanokim whyonchocerciasistransmissionpersistsafter15annualivermectinmassdrugadministrationsinsouthwestcameroon
AT piotrowskihelen whyonchocerciasistransmissionpersistsafter15annualivermectinmassdrugadministrationsinsouthwestcameroon
AT deanlaura whyonchocerciasistransmissionpersistsafter15annualivermectinmassdrugadministrationsinsouthwestcameroon
AT njouendouabdelj whyonchocerciasistransmissionpersistsafter15annualivermectinmassdrugadministrationsinsouthwestcameroon
AT ekanyarelindis whyonchocerciasistransmissionpersistsafter15annualivermectinmassdrugadministrationsinsouthwestcameroon
AT ndongmowinstonpatrickchounna whyonchocerciasistransmissionpersistsafter15annualivermectinmassdrugadministrationsinsouthwestcameroon
AT fungebuagallus whyonchocerciasistransmissionpersistsafter15annualivermectinmassdrugadministrationsinsouthwestcameroon
AT nnamdidumbuo whyonchocerciasistransmissionpersistsafter15annualivermectinmassdrugadministrationsinsouthwestcameroon
AT abongraphaela whyonchocerciasistransmissionpersistsafter15annualivermectinmassdrugadministrationsinsouthwestcameroon
AT bengamuamandrew whyonchocerciasistransmissionpersistsafter15annualivermectinmassdrugadministrationsinsouthwestcameroon
AT eyongmathiasesum whyonchocerciasistransmissionpersistsafter15annualivermectinmassdrugadministrationsinsouthwestcameroon
AT ndzeshangbertrandl whyonchocerciasistransmissionpersistsafter15annualivermectinmassdrugadministrationsinsouthwestcameroon
AT nkimbengdesmondakumtoh whyonchocerciasistransmissionpersistsafter15annualivermectinmassdrugadministrationsinsouthwestcameroon
AT teghensamuel whyonchocerciasistransmissionpersistsafter15annualivermectinmassdrugadministrationsinsouthwestcameroon
AT suirenganicetus whyonchocerciasistransmissionpersistsafter15annualivermectinmassdrugadministrationsinsouthwestcameroon
AT ashuernerstineebot whyonchocerciasistransmissionpersistsafter15annualivermectinmassdrugadministrationsinsouthwestcameroon
AT kahemmanuel whyonchocerciasistransmissionpersistsafter15annualivermectinmassdrugadministrationsinsouthwestcameroon
AT murdochmichelem whyonchocerciasistransmissionpersistsafter15annualivermectinmassdrugadministrationsinsouthwestcameroon
AT thomsonrachael whyonchocerciasistransmissionpersistsafter15annualivermectinmassdrugadministrationsinsouthwestcameroon
AT theobaldsally whyonchocerciasistransmissionpersistsafter15annualivermectinmassdrugadministrationsinsouthwestcameroon
AT enyongpeter whyonchocerciasistransmissionpersistsafter15annualivermectinmassdrugadministrationsinsouthwestcameroon
AT turnerjosephd whyonchocerciasistransmissionpersistsafter15annualivermectinmassdrugadministrationsinsouthwestcameroon
AT taylormarkj whyonchocerciasistransmissionpersistsafter15annualivermectinmassdrugadministrationsinsouthwestcameroon